Loading
A phase 3 trial of Inetetamab, Sirolimus protein-bound particles and Pyrotinib in Breast cancer, run by Peking Union Medical College, not yet recruiting.
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway is a phase 3 interventional study registered as NCT04736589 by Peking Union Medical College, with 270 participants planned, started 2021-02-02 and due to reach its primary completion in 2024-02-02. Interventions recorded: Inetetamab, Rapamycin, Pyrotinib, Chemotherapy. Conditions recorded: Breast Cancer.
Linked to the drug Inetetamab because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Inetetamab, Pyrotinib, Breast cancer (all types) and the tag pipeline.
Shares Inetetamab, Breast cancer (all types) and the tag pipeline.
Shares Pyrotinib and the tag pipeline.
Shares Pyrotinib and the tag pipeline.
Shares Pyrotinib and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/